{"schema_version":"1.0","type":"article","title":"ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.md","lang":"en","date":"2026-06-15","publish_at":"2026-06-15T10:35:00+08:00","updated_at":"2026-06-15","category":"醫學大會","topic":"醫學大會","tags":["ASCO","Oncology","RAS","ADC","PD-1 VEGF","In vivo CAR-T"],"summary":"ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"ASCO signal","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-01.png"},{"alt":"Practice-changing data","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-02.png"},{"alt":"Platform competition","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-15）。ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle。https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-15-2026-asco-car-t.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}